Antibodies
1 October 2014
XOMA Initiates U.S. Clinical Trial of Gevokizumab in Patients With Behcet’s Disease Uveitis – EYEGUARD(TM)-US1 October 2014
Celldex Announces Publication of Glembatumumab Vedotin Phase 1/2 Studies in the Journal of Clinical Oncology30 September 2014
Helix Reports on Interim Review of the Polish L-DOS47 Monotherapy Study in Non-Small Cell Lung Cancer30 September 2014
Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps29 September 2014
Roche presents encouraging update on metastatic bladder cancer data for anti-PDL1 medicine (MPDL3280A)29 September 2014
Roche presents preliminary combination data for anti-PDL1 medicine (MPDL3280A) with Avastin (bevacizumab)29 September 2014
Compugen Announces Presentations of Results for CGEN-15001 Supporting Immune Tolerance Induction29 September 2014
European Medicines Agency Validates the Marketing Authorization Application for Nivolumab in Non-Small Cell Lung Cancer29 September 2014
OncoMed’s Demcizumab Phase 1b Clinical Trials Show Encouraging Safety and Anti-Tumor Activity at ESMO29 September 2014
MSD Announces First Presentation of Data on the Investigational Use of Pembrolizumab in Patients with Advanced Gastric Cancer at ESMO 201427 September 2014
AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference27 September 2014
Bristol-Myers Squibb Announces Multiple Regulatory Milestones for Opdivo (nivolumab) in the U.S. and European Union26 September 2014
Roche’s Avastin and Xeloda show benefit for women with HER2-negative metastatic breast cancer in two new Phase III studies26 September 2014
Eureka Therapeutics raises $21 million in Series C to expand cancer immunotherapy pipeline25 September 2014
AbbVie’s HUMIRA® (adalimumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderately to Severely Active Crohn’s Disease25 September 2014
Novartis AIN457 (secukinumab) is the first ever IL-17A inhibitor to meet primary endpoint in two Phase III studies in psoriatic arthritis23 September 2014
Acceleron Provides Update on Externally Sponsored Clinical Trial of Dalantercept Monotherapy in Ovarian Cancer23 September 2014
Emergent BioSolutions Initiates Final Pivotal Study to Support Licensure of BioThrax at Large Scale23 September 2014
EPIRUS Announces Positive 58 Week Follow up Data for BOW015 for Treatment of Rheumatoid ArthritisNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports